Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.46 CHF | -1.97% | -3.96% | -3.57% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Mar. 27 | Santhera Pharmaceuticals Wins Priority Review for Duchenne Muscular Dystrophy Drug in China | MT |
Sales 2023 * | 8.29M 9.08M | Sales 2024 * | 51.09M 55.95M | Capitalization | 88.92M 97.37M |
---|---|---|---|---|---|
Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 * | 10.7 x |
Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 1.74 x |
P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 46 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 70.73% |
Latest transcript on Santhera Pharmaceuticals Holding AG
1 day | -3.37% | ||
1 week | -5.48% | ||
Current month | -4.71% | ||
1 month | -4.02% | ||
3 months | -4.61% | ||
6 months | -29.47% | ||
Current year | -5.10% |
Managers | Title | Age | Since |
---|---|---|---|
Dario Eklund
CEO | Chief Executive Officer | 56 | 19-11-30 |
Thomas Meier
FOU | Founder | 62 | 04-09-06 |
Andrew P. Smith
DFI | Director of Finance/CFO | 61 | 20-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Meier
FOU | Founder | 62 | 04-09-06 |
Director/Board Member | 56 | 17-04-03 | |
Otto Schwarz
BRD | Director/Board Member | 68 | 23-06-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 9.46 | -1.97% | 24 493 |
24-04-23 | 9.65 | +1.26% | 18,707 |
24-04-22 | 9.53 | +4.61% | 4,889 |
24-04-19 | 9.11 | -2.77% | 30,815 |
24-04-18 | 9.37 | -4.87% | 27,670 |
Delayed Quote Swiss Exchange, April 24, 2024 at 09:48 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-5.10% | 97.65M | |
+6.49% | 71.48B | |
+11.94% | 9.18B | |
-16.33% | 4.79B | |
+26.98% | 3.98B | |
+6.40% | 3.97B | |
+28.95% | 2.56B | |
-26.55% | 2.29B | |
-25.02% | 2.23B | |
+5.82% | 1.92B |
- Stock Market
- Equities
- SANN Stock